Abstract
Pancreatic ductal adenocarcinoma (PDAC) still remains one of the most fatal human malignant tumors. Long-term survival rate is still extremely pathetic even for patients who receive surgery. Epithelial-to-mesenchymal transition (EMT), which is a physiologic process of morphological as well as genetic changes in carcinoma cells, plays a vital role in aggressiveness of PDAC. Meanwhile EMT is also the reason why pancreatic cancer cells achieve such huge metastatic potentials. Many tumor microenvironmental factors such as cytokines, growth factors, as well as chemotherapeutic agents may induce EMT. Our study provides evidence regarding effects of EMT on pancreatic cancer progression, focusing on the correlation between EMT and other pathways which are crucial to tumor progression, especially vitamin D receptor signaling pathway. Research on signal pathways resulting in EMT inactivation during these disease processes may offer innovative ideas on plasticity of cellular phenotypes as well as possible therapeutic interventions.
Keywords: Pancreatic ductal adenocarcinoma, vitamin D receptor, epithelial-to-mesenchymal transition.
Current Pharmaceutical Design
Title:Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Volume: 21 Issue: 10
Author(s): Zhiwei Li, Junli Guo, Keping Xie and Shaojiang Zheng
Affiliation:
Keywords: Pancreatic ductal adenocarcinoma, vitamin D receptor, epithelial-to-mesenchymal transition.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) still remains one of the most fatal human malignant tumors. Long-term survival rate is still extremely pathetic even for patients who receive surgery. Epithelial-to-mesenchymal transition (EMT), which is a physiologic process of morphological as well as genetic changes in carcinoma cells, plays a vital role in aggressiveness of PDAC. Meanwhile EMT is also the reason why pancreatic cancer cells achieve such huge metastatic potentials. Many tumor microenvironmental factors such as cytokines, growth factors, as well as chemotherapeutic agents may induce EMT. Our study provides evidence regarding effects of EMT on pancreatic cancer progression, focusing on the correlation between EMT and other pathways which are crucial to tumor progression, especially vitamin D receptor signaling pathway. Research on signal pathways resulting in EMT inactivation during these disease processes may offer innovative ideas on plasticity of cellular phenotypes as well as possible therapeutic interventions.
Export Options
About this article
Cite this article as:
Li Zhiwei, Guo Junli, Xie Keping and Zheng Shaojiang, Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612821666141211151138
DOI https://dx.doi.org/10.2174/1381612821666141211151138 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirolimus and its Analogs and its Effects on Vascular Diseases
Current Pharmaceutical Design RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
Current Cancer Drug Targets Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex
Current Drug Therapy DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Current Cancer Drug Targets Epigallocatechin-3-Gallate Prevents Autoimmune-Associated Down- Regulation of p21 in Salivary Gland Cells Through a p53-Independent Pathway
Inflammation & Allergy - Drug Targets (Discontinued) Hepatitis C Virus Mediated Metastasis in Hepatocellular Carcinoma as a Therapeutic Target for Cancer Management
Current Drug Metabolism Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
Current Genomics Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews 4-aryl/heteroaryl-4H-fused Pyrans as Anti-proliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design High-Content Analysis of Kinase Activity in Cells
Combinatorial Chemistry & High Throughput Screening Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas
Current Gene Therapy